DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Switzerland
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
SDZ logo

Sandoz Group AG Stock Price

SWX:SDZ Community·CHF 28.9b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 65 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

SDZ Share Price Performance

CHF 66.74
18.88 (39.45%)
​
CHF 72.48
Fair Value
CHF 66.74
18.88 (39.45%)
7.9% undervalued intrinsic discount
CHF 72.48
Fair Value
Price CHF 66.74
AnalystConsensusTarget CHF 72.48
AnalystLowTarget CHF 55.07
AnalystHighTarget CHF 81.99
Thu, 3 Sep 26
Fair ValueCHF 72.48
Share Pricen/a

SDZ Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value CHF 72.48 7.9% undervalued intrinsic discount

Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach

1users have liked this narrative
0users have commented on this narrative
38users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value CHF 55.07 21.2% overvalued intrinsic discount

Rising Regulatory Hurdles And US Tariffs Will Undermine Biosimilar Margins

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value CHF 81.99 18.6% undervalued intrinsic discount

Rising Healthcare Demand And Aging Populations Will Accelerate Biosimilar Adoption

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
SDZ logo
Sandoz Group
7.9% undervalued intrinsic discount

Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 3 Sep
Read Narrative
SDZ logo
Sandoz Group
21.2% overvalued intrinsic discount

Rising Regulatory Hurdles And US Tariffs Will Undermine Biosimilar Margins

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 16 Aug
Read Narrative
SDZ logo
Sandoz Group
18.6% undervalued intrinsic discount

Rising Healthcare Demand And Aging Populations Will Accelerate Biosimilar Adoption

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 1 Apr
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
SDZ logo

SDZ: Biosimilar Expansion And Margin Shift Will Guide Future P/E Profile

Fair Value: CHF 72.48 7.9% undervalued intrinsic discount
38 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
SDZ logo

SDZ: Brazil Diabetes Entry And Legal Settlements Will Still Restrain Earnings Multiple

Fair Value: CHF 55.07 21.2% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
SDZ logo

SDZ: Future P/E Repricing And Biosimilar Expansion May Drive Re Rating

Fair Value: CHF 81.99 18.6% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Excellent balance sheet with reasonable growth potential.

0 Risks
3 Rewards
View Full Analysis

Sandoz Group AG Key Details

US$11.7b

Revenue

US$6.1b

Cost of Revenue

US$5.6b

Gross Profit

US$5.0b

Other Expenses

US$646.0m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
1.49
47.94%
5.53%
65.0%
View Full Analysis

About SDZ

Founded
1886
Employees
20000
CEO
Richard Saynor
WebsiteView website
www.sandoz.com

Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.

Recent SDZ News & Updates

User avatar
Narrative Update • Sep 03

SDZ: Biosimilar Expansion And Margin Shift Will Guide Future P/E Profile

Analysts have lifted the fair value estimate for Sandoz Group, with the implied price target moving higher by CHF 1.74 to CHF 72.48. They cite updated assumptions on discount rate, revenue growth, profit margins and future P/E that align with recent Street research pointing to a CHF 80 target.

Recent updates

No updates

Sandoz Group AG Competitors

LONN logo

Lonza Group

Symbol: SWX:LONN
Market cap: CHF 37.1b
GALD logo

Galderma Group

Symbol: SWX:GALD
Market cap: CHF 36.1b
BANB logo

Bachem Holding

Symbol: SWX:BANB
Market cap: CHF 5.8b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide